The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most consistent markers of bad prognosis for this disease. Dickkopf-3 (DKK3) is a secreted protein of the DKK family of Wnt regulators. It functions as a tumor suppressor in a range of cancers, including neuroblastoma. MYCN was recently found to downregulate DKK3 mRNA. In this study, we show that MYCN knockdown in MYCN-amplified (MNA) neuroblastoma cell lines increases secretion of endogenous DKK3 to the culture media. MicroRNAs (miRNAs) are $20 nt long single-stranded RNA molecules that downregulate messenger RNAs by targeting the 3# untranslated region (3#UTR). Many miRNAs regulate genes involved in the pathogenesis of cancer and are extensively deregulated in different tumors. Using miRNA target prediction software, we found several MYCN-regulated miRNAs that could target the 3#UTR sequence of DKK3, including mir-92a, mir-92b and let-7e. Luciferase expression from a reporter vector containing the DKK3-3#UTR was decreased when this construct was cotransfected with mir-92a, mir-92b or let-7e in HEK293 cells. Mutation of the mir-92 seed sequence in the 3#UTR completely rescued the observed decrease in reporter expression when cotransfected with mir-92a and mir-92b. Antagomir and miR-NA-mimic transfections in neuroblastoma cell lines confirmed that DKK3 secretion to the culture media is regulated by mir-92. Consistent with reports from other cancers, we found DKK3 to be expressed in the endothelium of primary neuroblastoma samples and to be absent in tumors with MYCN amplification. Our data demonstrate that MYCN-regulated miRNAs are able to modulate the expression of the tumor suppressor DKK3 in neuroblastoma.
Introduction
Neuroblastoma accounts for 7% of childhood malignancies and 15% of pediatric cancer-related deaths. It is a heterogenous disease, ranging from spontaneous regression to metastatic tumors resistant to multimodal treatment (reviewed in ref. 1) . The clinical outcome depends on several prognostic factors, with gene copy amplification of the MYCN oncogene being the most consistent marker of aggressive disease (2) . MYCN is a member of the MYC oncogene family, which also consists of c-myc and MYCL (3), and functions by up-and downregulating genes directly by promoter binding or through indirect pathways or mediators. It is known to regulate a wide range of microRNAs (miRNAs) (reviewed in ref. 4) , and is responsible for the methylation of target genes by activating methyltransferases, as well as affecting the chromatine structure (5, 6) .
MiRNAs are small non-coding RNAs which participate in diverse biological processes including tumorigenesis by sequence-specific targeting of particular messenger RNAs (mRNAs), primarily in the 3# untranslated region (3# UTR) (7) . MiRNAs negatively regulate protein production by translational repression, mRNA destabilization or a combination of both (8) . In mammals, miRNAs were recently shown to act predominantly through mRNA degradation (9) .
Dickkopf-3 (DKK3) is a member of the DKK family of secreted Wnt antagonists, including DKK1-4 and Soggy, a member resembling DKK3. The functions of other members of this family have been well elucidated, although the role of DKK3 still remains unclear (10, 11) . DKK3 functions as a tumor suppressor in a range of tumors (12) (13) (14) (15) (16) (17) (18) . DKK3 has also been shown to function as a tumor suppressor with prognostic significance in human neuroblastoma (19) . The tumor suppressor mechanisms of DKK3 include inhibition of the canonical Wnt signaling by blocking b-catenin translocation to the nucleus (13, 15, 17) . However, DKK3 does not seem to affect Wnt/b-catenin signaling in neuroblastoma, thereby suggesting other mechanisms to suppress tumorigenicity in this tumor (19) . This indicates that DKK3 has functions beyond mere canonical Wnt inhibition.
Previous reports have demonstrated that the expression of DKK3 mRNA in neuroblastic tumors and neuroblastoma cell lines is inversely correlated with the expression of the MYCN oncogene (19, 20) . By modifying MYCN expression with the use of MYCN shRNA and inducible MYCN expression, the reverse correlation to DKK3 mRNA expression was confirmed in several neuroblastoma cell lines. No direct binding to the DKK3 promoter was identified, which suggests an indirect regulatory mechanism (19) . We therefore hypothesized that MYCN suppresses DKK3 through miRNAs.
Material and methods

Cell cultures and miRNA overexpression
The human SH-SY-5Y neuroblastoma cell line was cultivated in a Dulbecco's modified Eagle's medium/Ham's F12 medium mixture (1:1) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% NEAA (non-essential amino acid). The HEK293 cell line was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The SK-N-AS, SK-N-BE(2), Kelly and SH-EP Tet21N cell lines were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum. SH-EP Tet21N cells express high MYCN in the absence of doxycycline (21) . To switch off MYCN expression, 1 lg/ml doxycycline was added to the growth media at least 24 h prior to the experiments. All cells were split before confluence and incubated at 37°C in a humidified incubator with 4.5% CO 2 .
MiRNAs mimics (let-7e, mir-92a, -92b, -17, -18a, -19a, -19b and -20a) and antagomirs (antimir-92a and -92b), with corresponding negative controls, were from Shanghai GenePharma (Shanghai, China). Transfections of miRNA mimics and antagomirs were carried out using Lipofectamine-2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
MYCN knockdown
SK-N-BE(2) and Kelly cells stably transfected with pcDNA6/TR (constitutively expressing the Tetracycline repressor) were transduced with a retrovirus (RV-aMN1658) containing a tetracycline-inducible anti-MYCN shRNA (aMN1658) expression module (22) . Retroviruses containing an inducible scrambled shRNA (SCR) were used as a negative control, and cells were cultivated as described previously (23) . Expression of the shRNAs was induced by adding 1 lg/ml doxycycline to the culture medium.
Abbreviations: DKK, Dickkopf; miRNA, microRNA; mRNA, messenger RNA; UTR, untranslated region.
Human tissue samples
Tissue samples from tumors were obtained from neuroblastoma patients during surgery, snap frozen in liquid nitrogen and transferred to storage at À80°C for future analysis. Twenty-six neuroblastoma samples derived from children of different ages and all clinical stages, including different biological subsets, were analyzed (Supplementary Table 2 is available at Carcinogenesis Online). Five childhood ganglioneuromas from children aged 12-25 months were also included. Genomic DNA was extracted from frozen (À70°C) tumor tissue according to standard procedures, and ethical approval was obtained by the Karolinska University Hospital Research Ethics Committee (approval 03-308).
Methylation-specific polymerase chain reaction DNA (100 ng) from neuroblastoma tumors or cell lines was bisulfite-treated using the EZ methylation gold kit (Zymo Research, Irvine, CA), and further purified using the DNA Clean and Concentrate Kit (Zymo). Previously published primers, specific to the methylated (ON-479/ON-480) and unmethylated sequence (ON-481/ON-482), were used to perform a methylation-specific polymerase chain reaction (PCR) on the promoter region of DKK3 (24) . The primer sequences are listed in Supplementary Table 1 , available at Carcinogenesis Online. The Zymotaq premix polymerase (Zymo) was used in a 25 ll reaction, including 50 ng of treated template. Products were visualized on ethidium bromide stained 3% agarose gels. We included DNA from the MDA-MB231 and HS578t as methylated and unmethylated controls, respectively (25) .
In silico target prediction Diana microT v3.0 (www.microrna.gr/microT), EMBLs MicroCosm Targets v5 (www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) and TargetScan v5.1 (www.targetscan.org/) target prediction software were used to identify miRNAs that could potentially target the human DKK3 3#UTR.
Luciferase reporter assay
The DKK3-3#UTR region was amplified from human total DNA (neuroblastoma LAN5 cell line) using primers ON-361 and ON-327 that contain in-fusion recombinase overhangs. The insert was cloned into the pMIR-REPORT vector (Ambion, Austin, TX) using the In-Fusion Cloning Kit (Clontech, Mountain View, CA) to generate pMIR-DKK3(wt). Mutations were introduced in the miRNA seed sequences at positions 25-31 (site 1), 550-556 (site 2) and 180-185 (site 3) using the Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with ON-447, ON-505 and ON-507 as primers to generate pMIR-DKK3(mut mir-92 seed), pMIR-DKK3(mut let-7 seed1) and pMIR-DKK3(mut let-7 seed2), respectively. A double mutant, pMIR-DKK3 (mut let-7 seed1 þ seed2), was also generated using ON-505 and ON-507 as primers. All vectors were verified by DNA sequencing using ON-005 and ON-363. The primer sequences are listed in Supplementary Table 1, available at Carcinogenesis Online HEK293 cells grown in 12-well plates were Lipofectamin-2000 transfected with 25 pmol synthetic miRNA or negative control, 0.05 lg pGL-renilla vector (Promega, Madison, WI) and 0.1 lg luciferase-UTR reporter vector [pMIR-DKK3(wt) and mutated versions]. Luciferase was measured two days after transfection using the dual luciferase reporter kit according to the manufacturer's instructions (Promega). Firefly luciferase was normalized against renilla luciferase. All experiments were performed at least three independent times with two parallels.
Quantitative polymerase chain reaction SH-SY-5Y cells were seeded in six-well plates and transfected with 100 pmol of synthetic miRNAs. Cells were harvested 48 h after transfection before total RNA was extracted and DNase-treated using the miRNeasy mini kit (Qiagen, Valencia, CA).
Complementary DNA was created using the miScript reverse transcriptase kit (Qiagen) and 1 ug RNA. Quantitative polymerase chain reaction was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA). DKK3 mRNA levels were quantified using HPRT1 and UBC as housekeeping genes. 2.5 ll of a Â20 diluted RT mix was loaded in a 25 ll reaction. The primer sequences are listed in Supplementary Table 1, available at Carcinogenesis Online The ABI 7300 (Applied Biosystems) was used as a detection system. DKK3 enzyme linked immunosorbent assay SH-SY-5Y and SK-N-AS cells were seeded in six-well plates and transfected in three parallels with 100 pmol of synthetic miRNAs or a negative control miRNA. The cell medium was changed 48 h after transfection, and the cells were then incubated for another 24 h before the conditioned medium was harvested for analysis using a DKK3 duoset enzyme linked immunosorbent assay (ELISA) assay (R&D Systems, Cambridge, UK). A high standard of 2 lM was chosen and diluted to a low standard of 15 nM.
The transfection of antagomirs and the measuring of the DKK3 levels secreted by the SK-N-BE(2) and Kelly cell line were performed in the same manner as the overexpression of synthetic miRNAs (Shanghai GenePharma). The cell medium was changed 24 h after transfection, whereas the harvesting of total cell protein and culture medium for ELISA was performed after another 24 h.
The human neuroblastoma cell lines Kelly and SK-N-BE(2), containing RVaMN1658 and RV-SCR constructs, were incubated in the presence of 1 lg/ml doxycycline for 6 days before analyzing the DKK3 content in the medium (23) . The medium was changed 24 h before analysis.
Levels of secreted DKK3 were normalized against total protein, measured at the time of harvesting, using the Biorad protein assay (Bio-Rad Laboratories, Hercules, CA).
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and graded alcohols, hydrated and washed in phosphate-buffered saline. After antigen retrieval on sodium citrate buffer (pH 6) in a microwave oven, the endogenous peroxidase was blocked by 0.3% H 2 O 2 for 15 min. Sections were incubated overnight at 4°C with a biotinylated goat anti-human DKK3 antibody (R&D Systems). Thereafter, sections were incubated with streptavidinhorseradish peroxidase (Invitrogen) for 30 min at room temperature. A matched isotype control and adsorption of the antibody with recombinant DKK3 (R&D Systems) were used as controls for nonspecific background staining. For colocalization studies of DKK3 and CD31, tumor tissue sections were simultaneously stained with biotinylated anti-human DKK3 and mouseanti-human CD31 (Dako, Glostrup, Denmark). For fluorescence visualization, streptavidin-Alexa Fluor 594 and anti-mouse Alexa Fluor 488 were used, respectively.
Affymetrix mRNA and miRNA reverse transcription-quantitative PCR expression analysis
The 95 neuroblastic tumors used for mRNA and miRNA expression analyses were from NB110, 110 neuroblastic tumors with documented clinical and genetic features: 88 neuroblastomas, 12 ganglioneuroblastomas and 10 ganglioneuromas obtained as described previously (19) . Tumor classification was according to (26, 27) , using only histological parameters. RNA isolation and mRNA analysis on the genome-wide mRNA expression platform (Affymetrix HG-U133 Plus 2.0, Santa Clara, CA) was as described previously (28) . Affymetrix probe sets were selected as described below. Intensity values and their P values were assigned to probe sets with GeneChipÒ Operating Software (GCOS) using the MASS5.0 algorithm (Affymetrix, Santa Barbara, CA). Samples were scaled by setting the average intensity of the middle 96% of all probe set signals to a fixed value of 100 for every sample in the dataset, enabling comparison of transcript levels between microarrays. Only expression values with a significant P value ('present call') were used. The TranscriptView genomic analysis and visualization tool were used to certify that the probe set selected had an antisense position in an exon of the gene (http://bioinfo.amc.uva.nl/human-genetics/transcriptview/). The verified probe sets selected for a gene showed the highest expression in any sample with a present call for that gene in that series: 209757_s_at (MYCN) and 214247_s_at (DKK3). The NB110 tumor series data have been deposited for public access in a MIAME-compliant format through the Gene Expression Omnibus (GEO) database at the NCBI website under GSE16476/GSE18271. miRNA profiling was performed as described in (29) . miRNA expression was normalized according to (30) , where single miRNA levels are calculated as an expression of the average expression of all 430 miRNA expression levels calculated for the tumor sample:-1 Â [C t (miRNA molecule)Àaverage C t (sample)]. All expression analyses were performed using R2; a microarray analysis and visualization platform developed in the Department of Human Genetics at the Academic Medical Center-University of Amsterdam. R2 can be accessed at: http://r2.amc.nl.
Statistics
All tests were performed two sided. Differences between two groups were studied using the two-sided Student's t-test. When more than two treatments were compared, we performed the one-way analysis of variance.
Gene-miRNA expression correlations (r and P) were calculated with a 2 log Pearson test. The significance of a correlation is determined by t 5 r/sqrt((1-r^2)/(n-2)), where r is the correlation value and n is the number of samples. Distribution measure is approximately as t with n-2 degrees of freedom ( Figure  5 and Supplementary Figure 2 is available at Carcinogenesis Online).
Results
MYCN knockdown increases secretion of DKK3 proteins in MYCNamplified neuroblastoma cell lines
The expression of DKK3 mRNA has previously been shown to be inversely correlated with MYCN mRNA expression in neuroblastic tumors and neuroblastoma cell lines (19,20,31) .
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Using a tetracycline-inducible retroviral MYCN shRNA expression system, we observed that MYCN knockdown increased the expression of DKK3 mRNA in the MYCN-amplified (MNA) neuroblastoma cell lines SK-N-BE(2) and Kelly ( Figure 1A) . Since DKK3 is a secreted glycoprotein, we further investigated DKK3 protein levels in culture supernatants from SK-N-BE(2) and Kelly cells upon induced MYCN knockdown. As shown in Figure 1B and C, increased levels of secreted DKK3 protein were detected. Similarly, SH-EP Tet21N, a derivative of the MYCN single copy SH-EP neuroblastoma cell line containing a constitutively expressed doxycycline-repressible MYCN gene revealed increased DKK3 secretion into the culture media when induced to suppress MYCN expression ( Figure 1D ).
These data clearly show an inverse correlation between MYCN expression and secretion of DKK3 proteins in neuroblastoma cell lines.
Methylation status of the DKK3 promoter in neuroblastoma Inactivation of DKK3 expression by promoter methylation has been shown in several cancers (12, 13, 24, 32) . We analyzed the methylation status of the DKK3 promoter in 10 primary neuroblastoma (five MNA, five non-MNA) samples and five neuroblastoma cell lines (three MNA, two non-MNA) using methylation-specific PCR. The breast cancer cell lines MDA-MB231 and HS578T were used as methylated and non-methylated DKK3 promoter controls, respectively (25) . As shown in Figure 2 , all neuroblastoma tumor samples and cell lines, irrespective of their MYCN status, showed specific amplification of the 150 bp band generated by the non-methylated primers.
These data demonstrate that the expression of DKK3 is not regulated by promoter methylation in neuroblastoma.
MYCN-regulated miRNAs are potential regulators of DKK3 expression In order to investigate whether MYCN regulates DKK3 expression indirectly through miRNAs, we used three independent miRNA target prediction programs (TargetScan v5.1, Diana-microT 3.0 and MicroCosm) to identify miRNAs that could target the 3#UTR of DKK3 transcripts. The analyses revealed that mir-92a, mir-92b and mir-32 were predicted to target the DKK3-3#UTR at position 25-31 (site-1) by all three programs used. In addition, let-7 and mir-98 were predicted to target a seed sequence at position 550-556 (site- MYCN (33-35) .
We have further analyzed the expression profile of MYCN mRNA and mir-92a in a series of 95 neuroblastic tumors (8 ganglioneuromas, 9 ganglioneuroblastomas and 78 neuroblastomas). In agreement with previous data, the analysis revealed a highly significant positive correlation between MYCN and mir-92a expression (Supplementary Figure  2 is available at Carcinogenesis Online, r 5 0.665, P 5 2.0 Â 10 À13 ). Since mir-92b has also been shown to correlate with MYCN expression (36) and was predicted to target DKK3, it was included in the further experiments to investigate miRNA:DKK3 mRNA interactions. In addition, we also investigated the binding of let-7e to the target sequence at site-2 of the DKK3-3#UTR.
The full-length 3#UTR sequence of DKK3 was cloned downstream of the Firefly luciferase gene in the pMIR-REPORT vector (pMIR-DKK3). HEK293 cells were cotransfected with pMIR-DKK3 and miRNA mimics of mir-92a, mir-92b, let-7e or a negative control miRNA (mir-NC). Luciferase assays revealed that an overexpression of mir-92a, mir-92b and let-7e significantly reduced luciferase activity from the reporter vector when compared with the negative control miRNA (Figure 3 ). We observed a 40, 32 and 33% decrease in luciferase activity with mir-92a, mir-92b and let-7e, respectively. These results indicate efficient repression of the luciferase DKK3-3#UTR Ã P , 0.05 versus respective control. Fig. 2 DKK3 promoter methylation status in neuroblastoma tumors and cell lines-methylation-specific PCR was performed on bisulfite-treated DNA from neuroblastoma tumors and cell lines. Lanes labeled U and M contain PCR products amplified from primers recognizing unmethylated and methylated DKK3 promoters, respectively. All neuroblastoma samples investigated were unmethylated. DNA from the breast cancer cell lines MDA-MB231 and HS578t were used as methylated and unmethylated controls, respectively (25) . NTC represents the no template control. MYCNamplified samples are marked with filled squares.
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reporter since large-scale proteomics studies have revealed that most miRNA:mRNA interactions result in the silencing of 30% (37) .
To test whether mir-92a, mir-92b and let-7e downregulated the luciferase activity of pMIR-DKK3 through direct binding to the predicted target sites, we mutated the putative seed sequences at site-1 and site-2. When the site-1 mutated version of pMIR-DKK3 (mut mir-92 seed) was coexpressed with mir-92a or mir-92b, the luciferase activity was rescued to levels similar to those observed for the negative control miRNA ( Figure 3A and B) . Only a slight rescue of luciferase activity was observed when the site-2 mutated reporter vector (mut let-7 seed1) was cotransfected with let-7e ( Figure 3C ). In searching for alternative let-7e seed sequences in the DKK3-3#UTR sequence, the RNA22 miRNA software detected a new candidate seed sequence at position 180-185 (site-3) (38) (Supplementary Figure 1b and c is available at Carcinogenesis Online). The mutated version of site-3 alone (mut let-7 seed2), or in combination with the mutated site-2 (mut let-7 seed1þ2), did not result in a major rescue of luciferase activity ( Figure 3C ).
Since mir-92a is coexpressed with the other members of the mir-17-92 cluster, we also examined the effect of these miRNAs on the 3#UTR sequence of DKK3. Cotransfection of pMIR-DKK3 and the individual mir-17-92 miRNA mimics resulted in a slight decrease in luciferase activity by mir-19a and -19b, which was predicted to target DKK3 by Targetscan. Cotransfections with mir-17 or mir-20a had no effect when compared with the negative control. We unexpectedly observed an increase in luciferase activity when the reporter vector was cotransfected with mir-18a (Supplementary Figure 3 is available at Carcinogenesis Online).
DKK3 secretion is regulated by mir-92a, mir-92b and let-7e in neuroblastoma cell lines To investigate how changes in the expression of MYCN-regulated miRNAs influence secretion of DKK3 in neuroblastoma, we transfected the non-MNA neuroblastoma cell lines SH-SY-5Y and SK-N-AS with the mir-92a, mir-92b and let-7e miRNA mimics. Overexpression of mir-92a and mir-92b resulted in a major reduction of secreted DKK3 proteins from SH-SY-5Y and SK-N-AS cells, whereas let-7e overexpression revealed a minor, but significant decrease ( Figure 4A ). Consistent with these results, DKK3 mRNA levels were reduced when SH-SY-5Y cells were transfected with miRNA mimics of mir-92a, mir-92b and let-7e (Supplementary Figure 4 is available at Carcinogenesis Online). Next, we transfected the MNA neuroblastoma cell lines SK-N-BE(2) and Kelly with antimir-92 (antagomir) to reduce the endogenous expression of mir-92. Quantification of endogenous mir-92s using a qRT-PCR assay revealed that the commercial antimir-92a and antimir-92b could not distinguish between mir-92a and mir-92b in Kelly cells (Supplementary Figure 5 is available at Carcinogenesis Online). Therefore, we used antimir-92a to reduce expression of mir-92a and mir-92b in MNA neuroblastoma cells. After 48 h of antimir-92 treatment, secretion of DKK3 into the culture media was measured. As shown in Figure 4B , suppression of mir-92s in SK-N-BE(2) and Kelly resulted in a 2.0-to 2.5-fold increase in DKK3 secretion when compared with an anti-mir-negative control (Antimir-NC).
In summary, these data show that the MYCN-regulated miRNAs mir-92a, mir-92b and let-7e reduce secretion of DKK3 proteins from human neuroblastoma cell lines.
DKK3 expression is inversely correlated to expression of mir-92 in neuroblastic tumors
When the mRNA expression level of DKK3 was analyzed and compared with the expression of mir-92a in the NB95-series of neuroblastic tumors, a striking inverse correlation was observed ( Figure 5 , r 5 À0.765, P 5 1.9 Â 10 À19 ). The ganglioneuromas and ganglioneuroblastomas, which were shown previously to express the highest level of DKK3 (19) , had significantly lower expression levels of mir-92a when compared with the neuroblastomas. Among the neuroblastoma tumors alone, the inverse correlation between DKK3 and mir-92a expression was also robust (r 5 À0.660, P 5 5.0 Â 10 À11 ).
These data strongly support our observations of mir-92a as a negative regulator of DKK3 expression in neuroblastoma.
DKK3 is expressed in neuroblastoma vasculature
We investigated 25 primary neuroblastoma tissue samples from various biological subsets and clinical stages for the expression of DKK3 (Supplementary Table 2 is available at Carcinogenesis Online). Twenty samples revealed specific DKK3 staining of the endothelial cells of the tumor, though no staining was seen in the tumor cells themselves ( Figure 6A ). Costaining with CD31 (an endothelial marker) demonstrated a colocalization to the endothelium. The immunopositivity for DKK3 in the endothelial cells varied in intensity between different tumors. All MNA tumors demonstrated very low or absent staining (Supplementary Table 2 is available at Carcinogenesis Online). The ganglioneuromas investigated were immunopositive for DKK3 in the tumor-derived ganglion cells, but not in the surrounding stroma ( Figure 6B , Supplementary Table 2 is available at Carcinogenesis Online).
Discussion
MYCN-regulated miRNAs decrease DKK3 secretion from neuroblastoma cell lines DKK3 is an established tumor suppressor gene that inhibits the proliferation of several cancers including neuroblastoma (18, 19, (39) (40) (41) (42) . It has previously been shown that DKK3 mRNA levels are inversely correlated to MYCN mRNA expression in neuroblastic tumors and neuroblastoma cell lines (19, 20) . In our study, we used an inducible retrovirally delivered anti-MYCN shRNA to downregulate MYCN expression in two MNA neuroblastoma cell lines and observed increased secretion of the endogenous DKK3 protein into the cell culture media. We also documented that the MYCN-regulated miRNAs, miR-92a, mir-92b and let-7e, efficiently decreased expression of a luciferase reporter containing the 3#UTR sequence from DKK3. The predicted target seed sequence for mir-92a and mir-92b in the DKK3-3#UTR sequence was validated by mutagenesis. Mutation of the Fig. 3 Luciferase assays for mir-92a, mir-92b and let-7e-luciferase activity of HEK293 cells cotransfected with the wild-type (pMIR-DKK3 wt) or mutated DKK3-3#UTR luciferase vector and miRNA mimics of mir-92a (A), mir-92b (B) or let-7e (C). Mut mir-92 seed is mutated in the predicted mir-92 seed sequence at positions 28-29 in DKK3-3#UTR. Similarly, mut let-7 seed1, mut let-7 seed2 and mut let-7 seed1 þ 2 were mutated in the predicted let-7 seed sequences at positions 550-556, 180-185 and 550-556 þ 180-185 in DKK3-3#UTR, respectively. A plasmid constitutively expressing Renilla luciferase was used for normalization of the data. Data shown are mean values ± SD of the ratio of normalized luciferase activity in miRNA mimic and control transfections. Negative controls are normalized to 1.
Ã P , 0.05 versus respective control. NS-no significance.
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putative let-7e seed sequences, separately or in combination, could not rescue the let-7e repression of luciferase reporter expression similar to that observed for the mir-92 seed sequence. This indicates that other as yet unidentified let-7e seed sequences and/or let-7e targets are responsible for the majority of the observed DKK3 repression by let7e. By the use of miRNA mimics and antagomir treatment, we further demonstrated that both DKK3 mRNA expression and protein secretion into the media were inversely correlated to mir-92a, mir-92b and let-7e expression in neuroblastoma.
Mir-92a is a member of the oncogenic mir-17-92 cluster, which consists of six coexpressed miRNAs: mir-17, mir-18a, mir-19a, mir19b, mir-20 and mir-92a. Members of this cluster have been shown to be aberrantly expressed and to promote tumorigenicity in neuroblastoma (33-35) as well as in other types of cancer (reviewed in ref. 43 ). 
Secretion of the tumor suppressor DKK3 in neuroblastoma
Several reports have documented a correlation between the expression of MYCN and the mir-17-92 cluster (33) (34) (35) . With the exception of mir92a, and to some extent mir-19a and -19b, none of the other mir-17-92 members reduced expression of the DKK3 3#UTR luciferase reporter. On the contrary, we observed an unexpected increase in luciferase activity when mir-18a was overexpressed. A similar observation has previously been reported and was proposed to be due to interference between mir-18a and regulation of the CMV promoter (44) .
The DKK3 promoter is not inactivated by hypermethylation in neuroblastoma Hypermethylation of CpG islands in the promoter region of genes is a powerful mechanism for transcriptional repression (reviewed in ref. 45) . Nonetheless, the differential methylation of promoters is not a general mechanism for regulating gene expression since most inactive promoters remain unmethylated (46) . DKK3 is frequently inactivated by promoter methylation in cancers of the gastrointestinal tract, lung, cervix and breast (12, 13, 15, 24, 32, 47) . For the neuroblastic tumors arising from the sympathetic adrenal lineage of the neural crest, increased DKK3 mRNA levels have been reported as a strong marker of differentiation. The well-differentiated ganglioneuromas showed a high DKK3 mRNA expression, whereas the undifferentiated neuroblastomas showed a low DKK3 expression, which also correlated with a bad prognosis (19) .
The c-myc protein has previously been shown to repress gene expression through promoter hypermethylation by interaction with Miz-1 and Dnmt3a (48) . Furthermore, global MYCN transcription factor-binding analysis in neuroblastoma has revealed an association of the MYCN protein to regions of DNA hypermethylation (49) .
We analyzed the methylation status of the DKK3 promoter in 10 neuroblastoma primary tumors and 5 neuroblastoma cell lines using methylation-specific PCR. The results revealed that neither the primary tumors nor the cell lines were hypermethylated at the investigated CpG island of the DKK3 promoter. In addition, a chromatin immunoprecipitation analysis performed by others failed to reveal a direct interaction between the MYCN protein and regulatory elements in the DKK3 promoter (19) .
These findings indicate that DKK3 levels in neuroblastoma are regulated by mechanisms other than promoter hypermethylation. Specifically, we have documented that mir-92a, mir-92b and let-7e target Table 2 , available at Carcinogenesis Online, Â600 magnification) and in differentiated ganglion cells of a benign ganglioneuroma (right image, sample no. 28 in Supplementary Table 2, available at Carcinogenesis Online, Â400 magnification).
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the 3#UTR sequence of DKK3 to repress its expression. Low levels of DKK3 have also previously been reported in the absence of promoter methylation in malignant melanoma cell lines (50) .
DKK3 expression in tumor endothelium is inversely correlated with MYCN levels DKK3 has been shown to be involved in tumor vessel biology and to be highly expressed in tumor endothelium (51) . DKK3 was reported to stimulate vascular growth and increase vascular density in tumors. We observed that the expression of the DKK3 protein in neuroblastoma vasculature was significantly higher in non-MNA tumors and more benign ganglioneuroma in comparison with MNA tumors. This is in line with a previous report by Koppen et al., who demonstrated higher levels of DKK3 mRNA expression in both non-MNA neuroblastoma tumors and ganglioneuromas (19) .
The mir-17-92 cluster has been related to angiogenesis (reviewed in ref. 43) . A recent work demonstrated that the in vivo inhibition of mir92a enhanced blood vessel formation (52) . Our novel findings provide one possible explanation for this observation since DKK3 has been shown to stimulate angiogenesis (51) .
The link between increased mir-92 expression in MYCN-amplified neuroblastoma cells and reduced DKK3 expression in the endothelial cells in the tumor is unclear. In this paper, we establish that mir-92 regulates expression of DKK3. There is a growing body of evidence that miRNAs not only functions as intracellular regulators but also as secreted effectors with paracrine and endocrine effects (53, 54) . We therefore speculate that the tumor endothelial cells could be affected by mir-92 released from MNA tumor cells in aggressive neuroblastomas. It should be investigated whether secreted MYCN-regulated miRNAs might be responsible for the low DKK3 expression in the endothelium of most aggressive tumors.
In some cellular settings, DKK3 has been shown to stimulate growth and inhibit apoptosis. Additionally, DKK3 could also stimulate or inhibit the canonical wnt pathway, depending on the cellular context (55) . These contradictory findings illustrate the complex and cell-specific nature of DKK3, so it is not surprising to find that DKK3 is regulated by miRNAs with postulated oncogenic as well as tumor suppressor functions.
